Extensive modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial

• Erik F. Eriksen,
• Roland Chapurlat,
• Rogely Boyce,
• Jacques P. Brown,
• Stéphane Horlait,
• Cesar Libanati,
• Yifei Shi,
• Rachel B. Wagman,
• Pascale Chavassieux

Affiliations

Erik F. Eriksen

Department of Clinical Endocrinology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Oslo University, Oslo, Norway

Roland Chapurlat

INSERM UMR 1033, University of Lyon, Lyon, France

Rogely Boyce

Amgen Inc., Thousand Oaks, United States

Jacques P. Brown

CHU de Quebec Research Centre and Laval University, Quebec City, Canada

Stéphane Horlait

Amgen, Boulogne Billancourt, France

Cesar Libanati

UCB Pharma, Brussels, Belgium; Corresponding author.

Yifei Shi

Amgen Inc., Thousand Oaks, United States

Rachel B. Wagman

Amgen Inc., Thousand Oaks, United States

Pascale Chavassieux

INSERM UMR 1033, University of Lyon, Lyon, France